Silver Book Fact

Widespread use of diabetes prevention drugs that enhance insulin sensitivity could result in a 50% prevention of type 2 diabetes over a 10 to 15 year period.

Shekelle, Paul G., Eduardo Ortiz, Sydne J. Newberry, Michael W. Rich, Shannon L. Rhodes, Robert H. Brook, and Dana P. Goldman. Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly. Health Aff. 2005; 24(2). https://www.ncbi.nlm.nih.gov/pubmed/16186152

Reference

Title
Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly
Publication
Health Aff
Publication Date
2005
Authors
Shekelle, Paul G., Eduardo Ortiz, Sydne J. Newberry, Michael W. Rich, Shannon L. Rhodes, Robert H. Brook, and Dana P. Goldman
Volume & Issue
Volume 24, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.  
  • Following the current path, diabetes cases will increase by 52.9% between 2003 and 2023. If an alternative path is taken, there will be 13.3% (2.8 million) fewer diabetes cases.  
  • Every additional dollar spent on the overall treatment of type 2 diabetes has produced health gains valued at $1.49.  
  • In general, for every 10 mmHg reduction in systolic blood pressure, the risk for any complication related to diabetes is reduced by 12%.  
  • The use of insulin pumps create net cost savings, including $5886 annually per person affected and $34.9 million in increased tax revenue